These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 30146451)

  • 1. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.
    Zori R; Thomas JA; Shur N; Rizzo WB; Decker C; Rosen O; Li M; Schweighardt B; Larimore K; Longo N
    Mol Genet Metab; 2018 Nov; 125(3):217-227. PubMed ID: 30146451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
    Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H;
    Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.
    Burton BK; Longo N; Vockley J; Grange DK; Harding CO; Decker C; Li M; Lau K; Rosen O; Larimore K; Thomas J;
    Mol Genet Metab; 2020 Aug; 130(4):239-246. PubMed ID: 32593547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial.
    Harding CO; Amato RS; Stuy M; Longo N; Burton BK; Posner J; Weng HH; Merilainen M; Gu Z; Jiang J; Vockley J;
    Mol Genet Metab; 2018 May; 124(1):20-26. PubMed ID: 29628378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria.
    Ishige M; Ito T; Hamazaki T; Kuwahara M; Lee L; Shintaku H
    Mol Genet Metab; 2023 Nov; 140(3):107697. PubMed ID: 37717412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials.
    Gupta S; Lau K; Harding CO; Shepherd G; Boyer R; Atkinson JP; Knight V; Olbertz J; Larimore K; Gu Z; Li M; Rosen O; Zoog SJ; Weng HH; Schweighardt B
    EBioMedicine; 2018 Nov; 37():366-373. PubMed ID: 30366815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.
    Longo N; Zori R; Wasserstein MP; Vockley J; Burton BK; Decker C; Li M; Lau K; Jiang J; Larimore K; Thomas JA
    Orphanet J Rare Dis; 2018 Jul; 13(1):108. PubMed ID: 29973227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.
    Zori R; Ahring K; Burton B; Pastores GM; Rutsch F; Jha A; Jurecki E; Rowell R; Harding C
    Mol Genet Metab; 2019; 128(1-2):92-101. PubMed ID: 31439512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegvaliase: Immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy.
    Hausmann O; Daha M; Longo N; Knol E; Müller I; Northrup H; Brockow K
    Mol Genet Metab; 2019; 128(1-2):84-91. PubMed ID: 31375398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria.
    Qi Y; Patel G; Henshaw J; Gupta S; Olbertz J; Larimore K; Harding CO; Merilainen M; Zori R; Longo N; Burton BK; Li M; Gu Z; Zoog SJ; Weng HH; Schweighardt B
    Clin Transl Sci; 2021 Sep; 14(5):1894-1905. PubMed ID: 34057292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses.
    Aryal M; Lau K; Boyer R; Zhou H; Abend J; Gu K; Olbertz J; Gupta S; Zoog S; Larimore K
    Mol Genet Metab; 2021 Nov; 134(3):235-242. PubMed ID: 34716085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program.
    Harding CO; Longo N; Northrup H; Sacharow S; Singh R; Thomas JA; Vockley J; Zori RT; Bulloch Whitehall K; Lilienstein J; Lindstrom K; Levy DG; Jones S; Burton BK
    Mol Genet Metab Rep; 2024 Jun; 39():101084. PubMed ID: 38694233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: Analysis of phase 3 clinical trial data.
    Rohr F; Burton B; Dee A; Harding CO; Lilienstein J; Lindstrom K; MacLeod E; Rose S; Singh R; van Calcar S; Whitehall K
    Mol Genet Metab; 2024 Mar; 141(3):108122. PubMed ID: 38184920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial rescue of neuropathology in the murine model of PKU following administration of recombinant phenylalanine ammonia lyase (pegvaliase).
    Goldfinger M; Zeile WL; Corado CR; O'Neill CA; Tsuruda LS; Laipis PJ; Cooper JD
    Mol Genet Metab; 2017 Sep; 122(1-2):33-35. PubMed ID: 28506393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.
    Longo N; Harding CO; Burton BK; Grange DK; Vockley J; Wasserstein M; Rice GM; Dorenbaum A; Neuenburg JK; Musson DG; Gu Z; Sile S
    Lancet; 2014 Jul; 384(9937):37-44. PubMed ID: 24743000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegvaliase therapy for phenylketonuria: Real-world case series and clinical insights.
    Scala I; Brodosi L; Gueraldi D; Manti F; Rovelli V; Zuvadelli J; Agnelli G; Cazzorla C; Nardecchia F; Giammanco A; Biasucci G
    Mol Genet Metab; 2024 May; 142(1):108151. PubMed ID: 38522180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term comparative effectiveness of pegvaliase versus medical nutrition therapy with and without sapropterin in adults with phenylketonuria.
    Burton BK; Clague GE; Harding CO; Kucuksayrac E; Levy DG; Lindstrom K; Longo N; Maillot F; Muntau AC; Rutsch F; Zori RT
    Mol Genet Metab; 2024 Jan; 141(1):108114. PubMed ID: 38142628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria.
    Bell SM; Wendt DJ; Zhang Y; Taylor TW; Long S; Tsuruda L; Zhao B; Laipis P; Fitzpatrick PA
    PLoS One; 2017; 12(3):e0173269. PubMed ID: 28282402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria.
    Longo N; Dimmock D; Levy H; Viau K; Bausell H; Bilder DA; Burton B; Gross C; Northrup H; Rohr F; Sacharow S; Sanchez-Valle A; Stuy M; Thomas J; Vockley J; Zori R; Harding CO
    Genet Med; 2019 Aug; 21(8):1851-1867. PubMed ID: 30546086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegvaliase: a novel treatment option for adults with phenylketonuria.
    Mahan KC; Gandhi MA; Anand S
    Curr Med Res Opin; 2019 Apr; 35(4):647-651. PubMed ID: 30247930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.